Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. Headquartered in Hampton, New Jersey, the company specializes in mast cell biology and immunology. Its lead product candidate, barzolvolimab (CDX-0159), is a humanized monoclonal antibody that specifically binds to and inhibits the KIT receptor, and is currently in late-stage clinical trials for chronic spontaneous urticaria, cold urticaria, prurigo nodularis, and eosinophilic esophagitis. Additionally, Celldex is advancing CDX-622, a bispecific antibody targeting complementary pathways to reduce mast cells and inhibit Type 2 inflammatory responses. As a clinical-stage entity, Celldex does not currently have any approved products on the market and relies on its proprietary immunotherapy platforms to discover and develop its pipeline of protein-based therapeutics.
